These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31619465)

  • 1. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models.
    Leclercq K; Matagne A; Provins L; Klitgaard H; Kaminski RM
    J Pharmacol Exp Ther; 2020 Jan; 372(1):11-20. PubMed ID: 31619464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of the antiepileptic drug candidate, padsevonil, on GABA
    Niespodziany I; Ghisdal P; Mullier B; Wood M; Provins L; Kaminski RM; Wolff C
    Epilepsia; 2020 May; 61(5):914-923. PubMed ID: 32297665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.
    Daniels V; Wood M; Leclercq K; Kaminski RM; Gillard M
    Br J Pharmacol; 2013 Jul; 169(5):1091-101. PubMed ID: 23530581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.
    Wu PP; Cao BR; Tian FY; Gao ZB
    Neurosci Bull; 2024 May; 40(5):594-608. PubMed ID: 37897555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein.
    Okada M; Fukuyama K; Shiroyama T; Ueda Y
    Biomed Pharmacother; 2021 Jun; 138():111462. PubMed ID: 33706129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family.
    Janz R; Südhof TC
    Neuroscience; 1999; 94(4):1279-90. PubMed ID: 10625067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.
    Niespodziany I; Rigo JM; Moonen G; Matagne A; Klitgaard H; Wolff C
    Epilepsia; 2017 Nov; 58(11):e157-e161. PubMed ID: 28850675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.